Your browser doesn't support javascript.
loading
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
Juan-Ribelles, Antonio; Bautista, Francisco; Cañete, Adela; Rubio-San-Simón, Alba; Alonso-Saladrigues, Anna; Hladun, Raquel; Rives, Susana; Dapena, Jose Luís; Fernández, Jose María; Lassaletta, Álvaro; Cruz, Ofelia; Ramírez-Villar, Gemma; Fuster, Jose Luís; de Heredia, Cristina Diaz; García-Ariza, Miguel; Quiroga, Eduardo; Del Mar Andrés, María; Verdú-Amorós, Jaime; Molinés, Antonio; Herrero, Blanca; López, Mónica; Márquez, Catalina; Toboso, María; Lendínez, Frencisco; Sirvent, Jose Gómez; Tallón, María; Rodríguez, Guiomar; Acha, Tomás; Moreno, Lucas; Fernández-Teijeiro, Ana.
Affiliation
  • Juan-Ribelles A; Pediatric Oncology and Hematology Unit, Hospital Universitari y Politécnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
  • Bautista F; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Cañete A; Pediatric Oncology and Hematology Unit, Hospital Universitari y Politécnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
  • Rubio-San-Simón A; Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • Alonso-Saladrigues A; Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu, Institut de Recerca San Joan de Déu (IRSJD), Barcelona, Spain.
  • Hladun R; Division of Pediatric Hematology and Oncology, Vall d'Hebron Comprehensive Cancer Center, Hospital Universitari Vall d'Hebrón, Passeig Vall d'Hebron 119, 08172, Barcelona, Spain.
  • Rives S; Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu, Institut de Recerca San Joan de Déu (IRSJD), Barcelona, Spain.
  • Dapena JL; Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu, Institut de Recerca San Joan de Déu (IRSJD), Barcelona, Spain.
  • Fernández JM; Pediatric Oncology and Hematology Unit, Hospital Universitari y Politécnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
  • Lassaletta Á; Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • Cruz O; Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu, Institut de Recerca San Joan de Déu (IRSJD), Barcelona, Spain.
  • Ramírez-Villar G; Department of Pediatric Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Fuster JL; Hospital Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
  • de Heredia CD; Division of Pediatric Hematology and Oncology, Vall d'Hebron Comprehensive Cancer Center, Hospital Universitari Vall d'Hebrón, Passeig Vall d'Hebron 119, 08172, Barcelona, Spain.
  • García-Ariza M; Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Osakidetza, Barakaldo, Bizkaia, Spain.
  • Quiroga E; Department of Pediatric Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Del Mar Andrés M; Pediatric Oncology and Hematology Unit, Hospital Universitari y Politécnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
  • Verdú-Amorós J; INCLIVA - Biomedical Research Institute, Hospital Clínico Universitario, Valencia, Spain.
  • Molinés A; Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Las Palmas, Spain.
  • Herrero B; Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
  • López M; Hematology Department, University Hospital Marqués de Valdecilla (IDIVAL), Santander, Spain.
  • Márquez C; Department of Pediatric Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Toboso M; Pediatric Oncology and Hematology Unit, Hospital Universitari y Politécnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
  • Lendínez F; Unidad de Oncohematologia Pediatrica. Hospital Infantil Universitario Torrecárdenas, Almeria, Spain.
  • Sirvent JG; Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
  • Tallón M; Hospital Alvaro Cunqueiro, Vigo, Spain.
  • Rodríguez G; Sofpromed, CRO para ensayos clínicos en España, Palma de Mallorca, Spain.
  • Acha T; Unidad de Oncología Pediátrica, Hospital Materno-Infantil Carlos Haya, Málaga, Spain.
  • Moreno L; Division of Pediatric Hematology and Oncology, Vall d'Hebron Comprehensive Cancer Center, Hospital Universitari Vall d'Hebrón, Passeig Vall d'Hebron 119, 08172, Barcelona, Spain. lucas.moreno@vallhebron.cat.
  • Fernández-Teijeiro A; Hospital Universitario Virgen Macarena, Seville, Spain.
Clin Transl Oncol ; 26(9): 2351-2359, 2024 Sep.
Article in En | MEDLINE | ID: mdl-38600340
ABSTRACT

INTRODUCTION:

ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.

METHODS:

The platform's database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.

RESULTS:

ECLIM-SEHOP has supported 47 studies 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.

DISCUSSION:

ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Registries / Clinical Trials as Topic / Neoplasms Limits: Child / Humans Country/Region as subject: Europa Language: En Journal: Clin Transl Oncol Year: 2024 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Registries / Clinical Trials as Topic / Neoplasms Limits: Child / Humans Country/Region as subject: Europa Language: En Journal: Clin Transl Oncol Year: 2024 Type: Article Affiliation country: Spain